Advertisement

Topics

"Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" Drugs and Medication Database: Page 2

02:25 EST 23rd February 2019 | BioPortfolio

Here are the most relevant "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" Drugs and Medications that we have found in our database.

More Information about "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" on BioPortfolio

We have published hundreds of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 news stories on BioPortfolio along with dozens of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Clinical Trials and PubMed Articles about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Companies in our database. You can also find out about relevant Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Drugs and Medications on this site too.

Showing "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" Drugs and Medications 26–29 of 29

Possibly Relevant

Tamiflu [rebel distributors corp]

These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for TAMIFLU. TAMIFLU (oseltamivir phosphate) capsules TAMIFLU (oseltamivir phosphate) for oral suspension Initial U.S. Appro

Krintafel [glaxosmithkline llc]

These highlights do not include all the information needed to use KRINTAFEL safely and effectively. See full prescribing information for KRINTAFEL. KRINTAFEL (tafenoquine) tablets, for oral useInitial U.S. Approval: 2018

Tremfya [janssen biotech, inc.]

These highlights do not include all the information needed to use TREMFYA safely and effectively. See full prescribing information for TREMFYA. TREMFYA (guselkumab) injection, for subcutaneous use Initial U.S. Approval: 2017

Alocril [allergan, inc.]

ALOCRIL (nedocromil sodium ophthalmic solution) 2% sterile



Advertisement
Quick Search
Advertisement
Advertisement